today emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research collaboration funding ...

Novartis has partnered with Versant Ventures to establish Borealis ... Novartis will offer upfront plus near-term research funding of up to $100, and holds the option for the acquisition of ...

Find out more about six immunology companies that have recently raised impressive funds in the biotech industry.

Vancouver-based Borealis Biosciences has emerged from stealth with $150 million USD ($202 million CAD) in backing from San Francisco-based founding investor Versant Ventures and ... in upfront and ...

Versant and Novartis joined forces in 2019 on ... The Swiss biotech emerged with $110 million in funding, $80 million from AZ, and a mission to develop a new generation of weight-loss therapies ...

Novartis has partnered with Versant Ventures to establish Borealis Biosciences ... Novartis will offer upfront plus near-term research funding of up to $100, and holds the option for the acquisition ...